SO3 Chromatography for Influenza Virus Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying influenza virus are inefficient in achieving high yield and purity, particularly for vaccine production, and do not effectively preserve the virus's immunogenicity and infectivity.
Innovation Solution
A process involving centrifugation, nuclease treatment, low conductivity buffer dilution, SO3 chromatography, and washing steps is employed to purify influenza virus, using monolithic columns and specific buffers to maintain virus integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional purification methods (ultra-filtration, ultra-centrifugation) are used, then virus concentration is achieved, but purity is insufficient and host cell contaminants remain
Solution Approach 1:
The patent changes the conductivity parameter of the buffer from conventional levels to low conductivity (≤5 mS/cm), which fundamentally alters the chromatographic separation mechanism. This parameter change enables the SO3 chromatography to achieve both high purity (99% removal of host cell proteins and DNA) and high productivity in a single step, resolving the contradiction between purification precision and efficiency
Solution Approach 2:
The patent uses a composite approach by combining SO3 functionalized chromatography support with low conductivity buffer conditions. This composite system creates a unique purification environment that simultaneously achieves high virus binding capacity and high purity, overcoming the limitations of traditional single-method approaches
2Manufacturing precision
If conventional chromatography is used, then some purification is achieved, but virus binding capacity is low and requires large column volumes
Solution Approach 1:
By changing the conductivity parameter to low levels (≤5 mS/cm) and using SO3 functionalization, the patent achieves a 30-fold increase in virus binding capacity. This allows the use of much smaller column volumes (e.g., 5 mL column for 500 mL virus sample) while maintaining high purification effectiveness, directly resolving the contradiction between purification effectiveness and quantity of material required
3Manufacturing precision
If strong purification methods are used to achieve high purity, then contaminants are removed, but virus infectivity and immunogenicity are compromised
Solution Approach 1:
The low conductivity buffer acts as an intermediary that enables gentle chromatographic conditions. It allows the SO3 chromatography to achieve 99% removal of host cell proteins and DNA while maintaining virus infectivity and immunogenicity, because the low ionic strength prevents harsh interactions that would damage the virus particles
Solution Approach 2:
The patent changes the conductivity parameter to low levels, which fundamentally alters the chromatography mechanism to be gentler on the virus. This parameter change enables achieving high purity through enhanced selectivity rather than harsh conditions, thus preserving virus reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high-purity, immunogenic, and infective influenza virus recovery, with up to 99% removal of host cell proteins and DNA, and a 30-fold increase in virus binding capacity compared to previous methods.
Implementation Method 1
subjecting said diluted fraction to a SO3 chromatography step
Implementation Method 2
incubating said fraction with a nuclease
Implementation Method 3
subjecting the cell culture to centrifugation to get a supernatant fraction of virus particles
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
The present invention refers to a process for purifying virus particles from cell culture, comprising the steps of subjecting the cell culture to centrifugation to get a supernatant fraction of virus particles, incubating said fraction with a nuclease, diluting the fraction with low conductivity buffer, subjecting said diluted fraction to a SO3 chromatography step, performing a washing step with low conductivity buffer, and eluting virus particles.